Bicara Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Bicara Therapeutics (BCAX) reported a net loss of $71.2 million for the third quarter of 2026, compared to a loss of $36.3 million in the prior year period. The increase in losses was driven by higher research and development expenses ($56.5 million) and general administrative costs as the company prepares for potential commercialization. Despite the widening loss, the company maintains a strong liquidity position with $442.3 million in cash and marketable securities, which management expects will fund operations through the first half of 2029. On the clinical front, Bicara provided significant updates regarding its lead candidate, ficerafusp alfa, for HPV-negative head and neck cancer. The pivotal FORTIFI-HN01 study has reached substantial enrollment levels, allowing for an interim analysis—including overall survival data—expected in mid-2027. Management also highlighted positive Phase 1b data, noting a median progression-free survival of 9.9 months, which they claim is approximately three times the rate reported for pembrolizumab monotherapy.
Tickers: $BCAX
Topics: clinical trials earnings report head and neck cancer net loss R&D expenses